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ABSTRACT 
The orexigenic peptide hormone ghrelin exerts potent inhibitory effects on pro-inflammatory 
cytokine release via the growth hormone secretagogue receptor-1a (GHS-R1a) on T cells and 
monocytes. As such, ghrelin is a promising therapeutic agent for the treatment of 
inflammatory conditions, but these effects depend on the availability of GHS-R1a. The aim 
of this study was to determine the effect of acute exercise on GHS-R1a expression on 
circulating CD14+ monocytes, total lymphocytes and CD3+ T cells.  Nine male club-
standard cyclists cycled for 1 h at 75% V
. O2peak (EX) or rested (REST) in a randomised cross-
over design. Compared with the equivalent times in REST, the concentration of circulating 
GHS-R1a+ lymphocytes and monocytes was higher in EX at immediately and 1 and 2 h post-
exercise (all p < .05).  The concentration of CD3+GHS-R1a+ cells was higher in EX than in 
REST immediately post-exercise only (258 (203) cells.μl-1 vs. 62 (42) cells.µl-1, p < .05). 
Density of GHS-R1a receptor expression was unaffected by trial or time.  Comparison of 
active participants at rest with 7 age-, sex- and BMI-matched sedentary controls revealed a 
higher concentration of GHS-R1a+ lymphocytes in active males (p < .05). These findings 
suggest a preferential recruitment of specific cell subpopulations expressing GHS-R1a into 
the peripheral circulation with acute and regular exercise.  Given that the anti-inflammatory 
effects of ghrelin depend on the availability of GHS-R1a, the preferential recruitment of 
subpopulations with high anti-inflammatory potential found here add a novel aspect to the 
potential mechanisms by which exercise acts to reduce pro-inflammatory cytokine levels.   
Key words: T cell, monocyte, ghrelin, inflammatory, growth hormone secretagogue receptor 
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Introduction 
There is increasing evidence of the coupling of immune status to the metabolic system 
(Dixit and Taub, 2005; Karalis et al., 2009; Odegaard and Chawla, 2013). This 
communication is mediated via a complex array of cytokines, hormones and neuropeptides. 
Ghrelin, an orexigenic peptide hormone, is predominantly produced by the X/A-like cells 
within the oxyntic mucosa of the stomach and has been primarily studied in relation to the 
regulation of food intake and its action in stimulating growth hormone release from the 
anterior pituitary gland.  Aside from these well-studied effects, ghrelin is now known to play 
a key role in the regulation of inflammation, with reports of inhibitory effects of the acylated 
(but not des-acylated) isoform of ghrelin on IL-1β, IL-6 and TNF-α mRNA and protein 
expression in both human and rodent T cells and monocytes in vivo and in vitro (Dixit et al., 
2004; DeBoer et al., 2008; Waseem et al., 2008).  Acylated ghrelin also attenuates leptin-
induced pro-inflammatory cytokine responses in human monocytes and T cells (Dixit et al., 
2004).  These cytokines are believed to mediate loss of appetite or anorexia commonly 
associated with inflammation, injury or illness (Kelley et al., 2003) and their overexpression 
can lead to a catabolic state and cachexia (Dixit and Taub, 2005).  With this in mind, 
acylated ghrelin has been proposed as a promising therapeutic agent for the treatment of a 
host of cachectic and other chronic inflammatory conditions including cancer cachexia, 
cardiovascular, respiratory and kidney diseases, inflammatory bowel diseases and age-
associated inflammation (Baatar et al., 2011;  DeBoer, 2011; Steinman and DeBoer, 2013).  
However, while initial findings have been promising, the safety of long-term ghrelin 
treatment is still unknown (Strasser et al., 2008; DeBoer, 2011). 
 
The effects of acylated ghrelin on immune cell cytokine release are dependent on the 
availability of its target receptor, the growth hormone secretagogue receptor-1a (GHS-R1a) 
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(Dixit et al., 2004).  GHS-R1a has been demonstrated on various immune cell subsets, 
including T cells, B cells, monocytes and neutrophils (Hattori et al., 2001; Dixit et al., 2004).  
Expression of GHS-R1a mRNA and protein by human T cells is increased by 3-4 fold upon 
activation with the mitogens phytohemagglutinin and concanavalin A, with similar results 
seen in LPS-stimulated monocytes (Dixit et al., 2004).  Considering that acute exercise at 
intensities of at least ~65-70% V
.
O2max is associated with an increased proportion of 
circulating activated T cells and monocytes (Woods et al., 2000; Walsh et al., 2011) it is 
plausible that exercise could promote an increase in the circulating availability of GHS-R1a 
on peripheral blood mononuclear cells (PBMCs). However, to date any effect of exercise on 
the expression of GHS-R1a on PBMCs has not been investigated. 
 
The purported ‘anti-inflammatory’ benefits of regular exercise have been the focus of much 
recent investigation.  Mechanisms suggested to be involved in the lowering of circulating 
levels of pro-inflammatory cytokines associated with a more active lifestyle  include muscle 
myokine release, alterations in circulating T cell and monocyte phenotype and altered 
macrophage phenotype within adipose tissue (Gleeson et al., 2011). It is an intriguing 
possibility that GHS-R1a expression on immune cells is an additional mechanism by which 
exercise regulates inflammatory cytokine production.  Additionally, participation in regular 
physical activity to dampen the expression of pro-inflammatory cytokines is also advocated 
in the treatment of many of the clinical conditions for which the efficacy of ghrelin therapy is 
also proposed.  Considering that the actions of acylated ghrelin on immune cell cytokine 
release are dependent on ligation with GHS-R1a, investigation of any interaction between 
exercise and immune cell GHS-R1a expression will provide valuable information concerning 
the potential for exercise to enhance the therapeutic benefits of acylated ghrelin treatment.  
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Therefore, the aim of the present study was two-fold: firstly to determine the effect of an 
acute bout of exercise on the expression of GHS-R1a on total circulating lymphocytes, CD3+ 
T cells and CD14+ monocytes in active individuals and secondly, to investigate any 
differences in these measures between regularly active and sedentary individuals at rest.  
METHODS 
Participants 
Nine male non-elite club-standard cyclists (mean ± SD: age 24 ± 2 years; height 178 ± 6 cm; 
body mass 72.4 ± 5.2 kg; body mass index (BMI) 22.8 ± 1.9 kg.m-2; V
.
O2peak 65.0 ± 8.5 
ml.kg-1.min-1) and 7 sedentary males (23 ± 2 years, height 181 ± 9 cm, weight 75.4 ± 13.0 kg, 
BMI 23.0 ± 2.3 kg.m-2) volunteered to participate in the experimental trials.  All participants 
were informed of the rationale for the study and, where applicable, the nature of the exercise 
tests to be performed before providing written informed consent.  The study protocol was 
approved by the local University Ethical Committee.  Participants were required to complete 
a comprehensive health-screening questionnaire prior to each visit to the laboratory and did 
not report any symptoms of infection and had not taken any medication during the 6 weeks 
prior to the study, nor were they currently on medication. All participants were non-smokers.  
Sedentary participants were defined as engaging in less than 30 min of moderate- or 
vigorous-intensity exercise per day and had done so for at least 3 months. All participants 
completed the short version of the validated International Physical Activity Questionnaire 
(IPAQ; http://www.ipaq.ki.se/downloads.htm; Craig et al., 2003) within a 2-week window 
either side of participating in the study to give an indication of activity levels.   
 
Acute Exercise: experimental design.  
The active participants attended the laboratory on four occasions; 2 preliminary visits (initial 
assessment of V
.
O2peak and familiarisation to the main exercise trial) and 2 experimental trials 
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(exercise trial: EX and resting trial: REST). Participants completed EX and REST in a 
randomised order at least 7 days apart.   
 
Preliminary exercise testing  
Approximately 1 week before the beginning of the main study each participant performed a 
continuous incremental exercise test on an electromagnetically braked cycle ergometer (Lode 
Excalibur Sport, Groningen, The Netherlands) to volitional exhaustion to determine peak 
oxygen uptake ( V
.
O2peak).  Participants began cycling at 95 W, with increments of 35 W 
every 3 min until volitional fatigue. Samples of expired gas were collected in Douglas bags 
during the 3rd min of each work rate increment and heart rates were measured continuously 
using short-range radio telemetry (Polar FSI, Polar Electro Ltd, Oy, Finland).  A 
paramagnetic oxygen analyser (Servomex 1420B, Crowborough, UK) and an infrared carbon 
dioxide analyser (Servomex 1415B) were used along with a dry gas meter (Harvard 
Apparatus, Edenbridge, UK) for determination of V
.
E, V
.
O2 and V
.
CO2. Gas analysers were 
calibrated according to the manufacturer’s instructions using a zero gas (100% N2), a 
calibration mix (16% O2 and 4% CO2) and atmospheric air.  The work rate equivalent to 75% 
V
.
O2peak was interpolated from the V
.
O2-work rate relationship. At this visit, height was 
measured to the nearest 0.1 cm using a stadiometer (Seca, Hamburg, Germany) and body 
mass was measured to the nearest 0.01 kg using an electronic scale (Avery, Birmingham, 
UK).   
 
Participants returned to the laboratory within 7 days of the V
.
O2peak test at a time of their 
choosing in order to acquaint themselves with the exercise trial procedures.  During this 
familiarisation trial, participants cycled on a stationary electrically braked cycle ergometer for 
60 min at 75% V
.
O2peak.  Expired air samples were obtained and analysed as described above 
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after the first 15 min and at 15-min intervals thereafter in order to ensure that the participants 
were exercising at the required intensity.  If the subject was exercising at ± 5% of the 
required intensity the work rate was adjusted accordingly; this occurred within 5 min of 
expired air sample collection.  Heart rates were monitored throughout this familiarisation trial.   
 
Main experimental trials 
 In an effort to standardise their nutritional status, participants were asked to eat the same 
foods and drinks during the 24-h prior to both experimental trials.  Participants were also 
asked to refrain from strenuous exercise, caffeine and alcohol during the 24-h before both 
main trials.  For both trials participants arrived at the laboratory at 09:30 h following an 
overnight fast of at least 10 h.  In EX only, participants were then required to empty their 
bladder before body mass (in shorts only) was recorded.  Subsequently, participants sat 
quietly for 10 min before an initial (pre-exercise) blood sample was collected from a 
superficial forearm vein.  At 10:00 participants began cycling on a stationary electrically 
braked cycle ergometer for 60 min at 75% V
.
O2peak.  Expired air samples and heart rate were 
monitored as in the familiarisation trial. Participants were allowed to consume water ad 
libitum for the duration of the main trials.  Further blood samples were collected immediately 
(11:00) and at 1 h (12:00) and 2 h (13:00) post exercise.  No further food or fluid intake was 
allowed until after the final blood sample had been collected.  Body mass (in shorts only) was 
recorded after the immediately post-exercise blood sample had been collected.  
 
In REST, participants rested quietly in the laboratory for 3 h, sitting reading, writing or 
working at a computer. Blood samples were taken at the same time of day as in EX (10:00, 
11:00, 12:00 and 13:00).  Mean ± SD laboratory conditions for all trials were 22.8 ± 0.7 °C 
and 42 ± 4% relative humidity. 
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Blood analyses 
Blood samples were collected into three evacuated blood collection tubes, two containing 
EDTA (1.6 mg EDTA/mL blood) and one containing sodium heparin (16 IU heparin/mL 
blood).   One of the tubes containing EDTA (7.5 ml) was used to determine total numbers of 
lymphocytes and monocytes and haematocrit and haemoglobin levels using a haematology 
analyser (AC.TTM 5diff analyser, Beckman Coulter, High Wycombe, UK). The intra-assay 
coefficient of variation for all measured variables was less than 3.0%.  Plasma volume 
changes were assessed from the haemoglobin and haematocrit values according to Dill and 
Costill (1974). All blood cell data were adjusted for plasma volume change relative to the 
first blood sample for each participant for each trial.  
 
Assessment of GHS-R1a expression on total lymphocytes, T cells and monocytes.  
Receptor quantification on circulating total lymphocytes, CD3+ T cells and CD14+ 
monocytes was determined by flow cytometry in heparinised whole blood, using Pharmingen 
monoclonal antibodies purchased from Becton Dickinson Biosciences, Oxford, UK and 
GHS-R1a receptor and IgG secondary antibody from Santa Cruz Biotechnology, Santa Cruz, 
CA.  A whole blood staining method was employed in order to minimally perturb the in vivo 
physiological status of GHS-R1a.  For each sample, duplicate 100 µl aliquots of heparinised 
whole blood were labelled with the monoclonal antibodies fluorescein isothiocyanate (FITC) 
conjugated anti-CD3 and phycoerythrin (PE) conjugated anti-CD14.  25 µl anti-GHS-R1a 
was subsequently added to one of the tubes only; the other tube acted as the negative control.  
All tubes were incubated on ice for 20 min, after which the erythrocytes were lysed with 
FACSTM Lyse (Becton Dickinson Biosciences, Oxford, UK) and incubated for a further 10 
min at room temperature in the dark.  Samples were centrifuged, the supernatant aspirated 
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and the cells resuspended.  25 µl allophycocyanin (APC) conjugated anti-donkey IgG F(ab’)2 
diluted 1:100 in HBSS was then added to all tubes before a further incubation for 10 min in 
the dark at room temperature.  Cells were then washed in ice cold PBS containing 0.1% 
bovine serum albumin and 2 mM EDTA (PBS/BSA/EDTA) before the leukocytes were 
resuspended in 400 µl PBS/BSA/EDTA.    
Three-colour flow cytometric analysis was carried out using a FACSCalibur flow cytometer 
with CellQuest analysis software (Becton Dickinson, Oxford, UK).  An unstained sample was 
used to set quadrant boundaries to allow accurate acquisition of stained samples.  100,000 
events were acquired per analysis. Side scatter versus forward scatter plots were used to gate 
on the lymphocyte population.  The percentage of gated lymphocytes expressing CD3 was 
derived from analysis of FL1 (CD3-FITC) versus FL4 (IgG-APC) dot plots. CD3+ cells were 
gated into a separate regions and estimation of absolute CD3+ numbers was derived from the 
total lymphocyte count.  Side scatter versus FL2 (CD14-PE) dot plots were used to gate on 
the monocyte population.  Histogram plots of cells incubated with the APC labelled IgG 
isotype control antibody alone (FL4) were used to define the threshold of positive staining for 
GHS-R1a on lymphocytes, CD3+ and CD14+ cells.  Histogram plots of the cells in the 
lymphocyte, CD3+ and CD14+ regions that positively expressed GHS-R1a conjugated to the 
secondary antibody IgG-APC (FL4) were subsequently used to calculate the percentage of 
that cell subpopulation expressing GHS-R1a.  Estimations of the concentration of circulating 
lymphocyte, CD3+ T cells and CD14+ monocytes expressing GHS-R1a were then calculated 
from the circulating cell counts. Geometric mean fluorescent intensity (GMFI), an indicator 
of the density of GHS-R1a expression on each cell, was also determined for lymphocytes, 
CD3+ T cells and CD14+ monocytes.  
Plasma acylated ghrelin concentration 
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Blood collected into the final tube was used for the determination of acylated ghrelin 
concentration, according to Broom et al. (2007).  This tube contained EDTA and p-
hydroxymercuribenzoic acid to prevent the degradation of acylated ghrelin by protease. The 
samples were subsequently spun at 1500 g for 10 min in a refrigerated centrifuge at 4°C. 
Supernatants were separated into eppendorf tubes and 100 µl of 1M HCL were added per ml 
of plasma. Samples were spun in a refrigerated centrifuge at 1500 g for a further 5 min at 4°C. 
Supernatants were separated into eppendorf tubes and stored at -80°C for later analysis.  
Plasma acylated ghrelin concentrations were determined by commercially available ELISA, 
according to the manufacturer’s instructions (SPI BIO, Montigny le Bretonneux, France).  To 
eradicate interassay variation, samples from each participant were analysed in the same run.  
The intra-assay coefficient of variation was 3.3%. Data are presented for 8 participants; due 
to a problem with the p-hydroxymercuribenzoic acid preservative in the samples from 1 
participant.  
 
Comparison with sedentary participants 
Sedentary participants arrived at the laboratory at 09:45, following an overnight fast of at 
least 10 h and having avoided caffeine, alcohol and strenuous exercise during the previous 24 
h.  After sitting quietly for 10 min, a single blood sample was collected from a superficial 
forearm vein.  Participants were then free to leave the laboratory.  GHS-R1a analysis on total 
lymphocytes, CD3+ T cells and CD14+ monocytes was performed as above.   
 
Statistical Analysis. 
Data in the text, tables and figures are presented as mean values and their standard deviation 
(± SD).    The data were examined using a two-factor (trial x time) analysis of variance 
(ANOVA) with repeated measures design.  Assumptions of sphericity were checked and, 
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where appropriate, the adjustments to the degrees of freedom for the ANOVA were made 
using the Huynh-Feldt method of correction. Any significant F ratios subsequently shown 
were assessed using Student’s paired t-test to determine which values were significantly 
different with the Bonferroni correction for multiple comparisons applied to the unadjusted p 
value. Effect sizes (ES) based on eta2 are provided for all significant data to give an 
indication of the proportion of the variation attributable to trial or group, using Cohen’s 
definition of eta2 of 0.01, 0.06 and 0.14 representing 'small', 'medium' and 'large' effects, 
respectively (Cohen, 1988).  Comparisons between active and sedentary participants were 
assessed using the first sample from the active participants’ resting trials with the 
independent t-test applied.  Comparison of the area under the curve for the ghrelin values was 
assessed using the paired-samples t-test.  Statistical significance was accepted at p < .05. All 
results were analysed using Statistical Software Package for Social Sciences (SPSS) software 
version 20.0 for Windows (SPSS, Chicago, IL). 
 
RESULTS 
Physiological responses to exercise 
Mean % V
.
O2peak during EX was 73.1 ± 3.7%,  mean heart rate was 168 ± 7 beats.min-1 and 
mean RPE was 16 ± 1. After exercise the mean decrease in body mass (corrected for fluid 
intake) was 1.1 ± 0.2 kg.  There was no significant time x trial interaction effect for changes 
in plasma volume relative to the first blood sample; after exercise plasma volume had 
decreased by 5.7 ± 3.4% and had decreased by 0.5 ± 5.3% at the equivalent point in REST.  
Total lymphocytes 
There was a significant interaction between trial and time for the concentration of circulating 
lymphocytes (interaction, F (3,24) = 10.0, p = .001, ES = 0.56;  Table 1). At post-exercise in 
EX, concentrations were higher than at the equivalent time in REST (p <.01) and lower at 2 h 
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post-exercise than at the equivalent time in REST (p <.05).   There was a significant 
interaction between trial and time for the concentration of lymphocytes expressing GHS-R1a 
(interaction F (3,24) = 8.2, p = .001, ES= 0.51; Figure 1).    Concentrations were higher in EX 
at post-exercise, 1 h and 2 h post-exercise than in REST at the equivalent time points (p < .01, 
p < .05 and p < .05, respectively).  There was a significant interaction between trial and time 
for the proportion of lymphocytes expressing GHS-R1a (interaction F (3,24) = 5.8, p =.029, ES 
= 0.42; Table 1).   Values were higher in EX at 1 h and 2 h post-exercise than at the 
equivalent times in REST (p < .01 and p <.05, respectively).  There was no significant trial x 
time interaction or main effects for trial or time evident for the GMFI of GHS-R1a on 
lymphocytes (Table 1).  
CD3+ T cells 
There was a significant interaction between trial and time for the concentration of CD3+ T 
cells (interaction, F (3,24 )= 10.1, p = .001, ES  = 0.59; Table 1).   At post-exercise in EX, 
CD3+ concentration was higher than at the equivalent time in REST (p < .02).  At 2 h post-
exercise CD3+ concentration was lower than at the equivalent time in REST (p < .05).  There 
was a significant interaction between trial and time for the concentration of CD3+ T cells 
expressing GHS-R1a (interaction F (3,24) = 8.9, p = .007, ES = 0.53; Figure 2), with 
concentrations higher in EX at post-exercise than at the equivalent time point in REST (p 
< .02).  Similarly, there was a significant interaction between trial and time for the proportion 
of CD3+ T cells expressing GHS-R1a (interaction F (3,24) = 6.4, p =.002, ES = 0.45; Table 1); 
values were also higher in EX immediately post-exercise than at the equivalent times in 
REST (p <.01).  There was no significant trial x time interaction or main effects for trial or 
time evident for the GMFI of GHS-R1a on CD3+ T cells (Table 1).  
 
Monocytes 
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There was a significant interaction between trial and time for the concentration of CD14+ 
monocytes (interaction, F (3,24) = 3.1, p = .047, ES = 0.28; Table 1).   Circulating CD14+ 
monocyte concentration was higher in EX at 1 h and 2 h post-exercise than at the equivalent 
time points in REST (both p < .01).  There was a significant interaction between trial and 
time for the concentration of CD14+ monocytes expressing GHS-R1a (interaction F (3,24) = 
4.1, p = .018, ES = 0.34; Figure 3), with concentrations higher in EX at immediately, 1 h and 
2 h post-exercise than in REST at the equivalent time points (p < .02, p < .01, p < .02, 
respectively).  Similarly, there was a significant interaction between trial and time for the 
proportion of CD14+ monocytes expressing GHS-R1a (interaction F (3,24) = 4.1, p = .030, ES 
= 0.34; Table 1), with values higher in EX at 1 h and 2 h post-exercise than at the equivalent 
times in REST (p < .05 and p < .01, respectively).  There was no significant trial x time 
interaction or main effects for trial or time evident for the GMFI of GHS-R1a on CD14+ 
monocytes (Table 1).  
  
Plasma acylated ghrelin concentration 
There was a significant trial x time interaction effect (F (3,21) = 6.8, p =.002, ES =  0.50) for 
plasma acylated ghrelin concentration, with values significantly lower at immediately and 1 h 
post-exercise in EX compared with the equivalent time points in REST (p <.001 and p < .05, 
respectively) (Figure 4).  Area under the curve for plasma acylated ghrelin concentrations 
was lower in EX than REST (199 ± 71 pg.ml-1.3 h vs. 338 ± 136 pg.ml-1.3 h , t (7) = 4.32, p < 
.01, ES = 0.70). 
 
Comparison between active and sedentary participants at rest  
Median IPAQ activity scores were 3173 (range 1158-4812) MET-min.week-1 in the active 
participants and 317 (range 132-436) MET-min.week-1 in the sedentary participants.  IPAQ 
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guidelines define a low activity score as less than 600 MET-min.week-1.  In the active group, 
activity was equivalent to approximately 3 h of vigorous and 3 h of moderate activity per 
week.  There were no significant differences between the active and sedentary participants for 
circulating cell counts, proportion of monocytes and T cells expressing GHS-R1a and the 
density of GHS-R1a expression on lymphocytes, T cells and monocytes (Table 1).  However 
the proportion of lymphocytes expressing GHS-R1a was higher in active compared with 
sedentary participants (t (14) = 2.21, p < .05, ES = 0.26, respectively, Table 1).  The 
concentration of lymphocytes expressing GHS-R1a was also higher in active participants 
(234 ± 130 cells.μl-1 vs. 93 ± 76 cells.μl-1, t (14) = 2.53, p < .05, ES = 0.35), but there were no 
differences in the concentration of CD3+GHS-R1a+ cells (59 ± 38 cells.μl-1 vs. 73 ± 67 
cells.μl-1) and CD14+GHS-R1a+ cells (50 ± 22 cells.μl-1 vs.  65 ± 14 cells.μl-1) between the 
active and sedentary groups.  
 
DISCUSSION  
The principal finding of the present study was that an acute bout of strenuous exercise was 
associated with an increase in both the concentration and proportion of total lymphocytes, 
CD3+ T cells and CD14+ monocytes expressing the specific receptor for acylated ghrelin, 
GHS-R1a, yet the density of receptor expression was unaffected by exercise.  We also report 
higher GHS-R1a expression on lymphocytes at rest in the active males compared with a 
group of age-, sex-, and BMI-matched sedentary counterparts.   
To the authors’ knowledge, this study is the first to show a substantial effect of exercise on 
the circulating proportion and concentration of lymphocytes, T cells and monocytes 
expressing GHS-R1a.  The fact that the density of expression of the receptor on each cell type 
was unchanged by exercise suggests that the increase is related to a preferential recruitment 
of cells with a propensity for GHS-R1a expression, rather than any up regulation of receptor 
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expression per se.  We chose to assess the GHS-R1a response to exercise chiefly on T cell 
and CD14+ monocytes because the ability of ghrelin to attenuate pro-inflammatory cytokine 
release from PBMCs is dependent on the availability of this specific receptor (Dixit et al., 
2004).  Future investigations should determine which of the recruited CD3+ and CD14+ 
subsets are expressing GHS-R1a. It seems plausible that the subpopulations that are more 
metabolically and inflammation-active will have higher expression, i.e. CD16+ monocytes 
and the effector memory and senescent CD45RA+ effector memory CD8+ T cell 
subpopulations (Appay et al., 2008; Ziegler-Heitbrock et al., 2010).   Of particular note, 
responses in CD3+ T cells did not fully account for the expression of GHS-R1a observed in 
total lymphocytes.  GHS-R1a is also expressed on human B lymphocytes and NK cells 
(Hattori et al., 2001, Taub et al., 2010), therefore it is likely that an increase in GHS-R1a+ 
NK cells and B cells contributed to the total lymphocyte response.  In particular, acylated 
ghrelin is reported to exert potent inhibitory effects on the mRNA and protein expression of 
IL-1β and TNF-α by NK cells in vitro (Taub et al., 2010). 
The recruitment of lymphocytes and monocytes into the circulation is largely related to 
adrenergic-mediated demargination and extravasation of sequestered cells (Shephard, 2003; 
Kruger et al. 2008), with cell subpopulations that are selectively deployed in response to an 
exercise stimulus also being those with the greatest expression of β2-adrenoreceptors or with 
greatest affinity for epinephrine (Shephard, 2003; Dimitrov et al., 2010).  These recruited 
cells appear also to be those with potent effector/cytotoxic functions whereas those that 
preferentially transmigrate into the tissues have tissue migratory phenotypes (Simpson et al., 
2008; Turner et al., 2010). In this way there appears to be a selective deployment of specific 
cell subpopulations that are deemed most able to respond effectively to an 
immune/inflammatory challenge (Dhabhar, 2009).  Taking this view in the context of the 
present study, enhanced recruitment of GHS-R1a+ monocytes and lymphocytes with acute 
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exercise implies that these subpopulations have a high expression of β2-adrenoreceptors and 
potentially provides a circulating population of cells with high anti-inflammatory potential 
available for tissue migration.  Indeed, numbers of GHS-R1a+ T cells peaked immediately 
after exercise and returned to baseline values within the first hour after exercise, whereas the 
concentration of total lymphocytes expressing GHS-R1a remained above that in REST even 
at 2 h post-exercise.  While this may indicate remargination of the GHS-R1a+ T cell 
subpopulation, it may also suggest preferential migration of this specific subpopulation into 
the tissues.  In support for this, GHS-R1a ligation in human T cells is associated with actin 
polymerisation and actin distribution changes consistent with a role in cell signalling and 
trafficking (Dixit et al., 2004). 
The finding of higher concentrations and proportion GHS-R1a+ lymphocytes in active 
compared with sedentary participants at rest also supports a role of GHS-R1a in the reduction 
of circulating pro-inflammatory cytokines in regularly active individuals. While this finding 
needs to be confirmed in a larger cohort, elevated numbers of circulating lymphocytes 
expressing GHS-R1a at rest may represent a chronic adaptation to successive acute exercise 
bouts whereby a population of cells that are best adapted to respond quickly to inflammation, 
illness or injury are preferentially deployed (Dhabhar, 2009).  
Immune cell expression of GHS-R1a declines with age and has been related to age-associated 
thymic involution and increased levels of systemic inflammation (Dixit and Taub, 2005; 
Dixit et al., 2009).  Indeed ghrelin and GHS-R1a knockout mice exhibit reduced thymocyte 
counts and more pronounced age-dependent thymic involution than in wild type mice (Dixit 
et al., 2007).  Ghrelin expression by T cells is also reduced in ageing mice and ghrelin 
infusion in this model has been shown to reduce levels of IL-6, TNF-α and IL-1β (Dixit et al., 
2009).   Ghrelin infusion to improve lean body mass and appetite and decrease circulating 
inflammatory cytokines has had positive outcomes in patient populations with inflammation–
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related cachexia including cachetic cancer, cardiovascular disease, chronic obstructive 
pulmonary disease and chronic kidney disease (DeBoer, 2011; DeBoer et al., 2008; Nagaya et 
al., 2004, 2005; Strasser et al., 2008).  Our finding of increased GHS-R1a availability after 
exercise and a higher circulating proportion and concentration of GHS-R1a+ lymphocytes in 
active compared with sedentary individuals suggests that exercise prescription should be 
explored further as a tool to enhance the effectiveness of ghrelin therapy.  Ghrelin is reported 
to be safe and well tolerated at doses of up to 10 μg.kg-1 (total ghrelin, Nagaya et al., 2001; 
Strasser et al., 2008) and 5 μg.kg-1 (acylated form; Akamizu et al., 2004) in both patient 
populations and healthy individuals with plasma concentrations of acylated ghrelin increasing 
by at least 30-fold after administration to around 3000-4000 pg.ml-1 (3-4 ng.ml-1) (Akamizu 
et al., 2004).  Adverse effects of ghrelin administration are seemingly few; reports of short-
lasting (minutes) and relatively mild abdominal discomfort and flushing are common and 
increases in plasma glucose and decreases in plasma insulin levels are also reported 
(Akamizu et al., 2004; Strasser et al., 2008).  However, there are still unanswered questions 
concerning the effect of long-term ghrelin administration on growth hormone-mediated 
stimulation of tumour growth and there is the potential for ghrelin resistance with high 
plasma levels over a long period of time (Strasser et al., 2008).  In this regard and considering 
the increased availability of GHS-R1a with exercise, future in vitro work should determine 
whether the concentration of acylated ghrelin required to elicit inhibitory effects on T cell and 
monocyte inflammatory cytokine release is lower after acute exercise or in active compared 
with sedentary individuals at rest.  
In the present study, plasma levels of acylated ghrelin were temporarily suppressed after 
acute exercise, in accordance with previous literature (Broom et al., 2007; King et al., 2010).   
The reasons for this fall are unclear, but are thought to be related to reduced blood flow to the 
splanchnic regions with exercise (King et al., 2013).  This could interfere directly in the 
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release of acylated ghrelin into the circulation or reduce oxygen supply thus affecting the 
ability of ghrelin to become acylated via actions on ghrelin O-acyltransferase activity within 
the Golgi apparatus.  Additionally augmented de-acylation by circulating proteases/esterases 
may also be involved (King et al., 2013).  While there is no evidence to suggest that ghrelin 
directly regulates GHS-R1a expression, it could be argued that this limits the availability of 
ghrelin to bind to GHS-R1a on peripheral immune cells and exert its inhibitory effect on pro-
inflammatory cytokine release, regardless of the exercise-associated increases in GHS-R1a+ 
PBMCs found here.  Although the effect of post-exercise ghrelin levels on PBMC cytokine 
release was not assessed here (and was not the focus of the study), it should be noted that 
plasma acylated ghrelin levels had returned to baseline levels at 2 h post-exercise, whereas 
the impact of exercise on GHS-R1a expression persisted for monocytes and lymphocytes at 
this time. Therefore, any negative influence would be relatively short-lived.  In the present 
study circulating concentrations of acylated ghrelin fell to ~40 pg.ml-1 (0.04 ng.ml-1) after 
acute exercise.  In vitro inhibition of T cell and monocyte cytokine production via ligation 
with GHS-R1a is reported at concentrations ranging from 1-1000 ng.ml-1 (Dixit et al., 2004; 
Waseem et al, 2008).  The effect of acylated ghrelin at concentrations of less than 1 ng.ml-1 
has not been determined.  However, both acylated and des-acylated ghrelin are also secreted 
by human monocytes and T cells, with secretion increasing rapidly upon activation and 
peaking after 48 h (Hattori et al., 2001, Dixit et al., 2004; Dixit et al., 2009).  The amount 
secreted is not insignificant; activated T cells can produce between 300 and 800 pg.ml-1 of 
total ghrelin upon activation and can also express the pre-pro form of ghrelin in their Golgi 
bodies, where it is presumably cleaved to its mature form (Dixit et al., 2004).  This suggests 
that ghrelin acts to regulate cell function within the immune microenvironment in an 
autocrine/paracrine manner. Acute exercise is also known to activate T cells and monocytes 
(Woods et al., 2000; Walsh et al., 2011) and thus it may be speculated to stimulate ghrelin 
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secretion by PBMCs to act locally; this requires confirmation.  Circulating acylated ghrelin 
also has a half-life of just 9-13 min (Akamizu et al., 2004). For these reasons, it is proposed 
that ghrelin concentrations are able to reach biologically high levels within the local 
microenvironment that are not restricted by circulating concentrations (Dixit et al., 2004).  
Taken together, the current literature suggests that reductions in plasma concentrations of 
acylated ghrelin after exercise will not necessarily compromise ghrelin availability in the 
immune microenvironment.     
In summary, the present study is the first to demonstrate the preferential recruitment of 
peripheral circulating lymphocytes, T cells and monocytes expressing GHS-R1a in response 
to acute exercise and higher concentrations of GHS-R1a+ lymphocytes in active compared 
with sedentary young, healthy males at rest.  Given that the established inhibitory effects of 
acylated ghrelin on pro-inflammatory cytokine expression are dependent on GHS-R1a 
expression, these findings suggest that GHS-R1a expression may be an additional avenue by 
which exercise exerts anti-inflammatory effects.  Furthermore, these findings have substantial 
implications for the use of exercise prescription to augment the promising therapeutic effects 
of exogenous ghrelin and ghrelin mimetics in the treatment of long-term inflammatory 
illnesses and age-associated inflammation.  Future work needs to determine optimal exercise 
prescription in both clinical and healthy older populations to maximise GHS-R1a expression 
on inflammatory immune cells.   
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Figure legends 
Figure 1. Concentration of circulating lymphocytes expressing GHS-R1a in response to 1 h 
cycling at 75% V
.
O2peak (EX) or rest (REST).  Values are means ± SD, n = 9.  Significantly 
higher than REST at that time, *, p < .05; **, p < 0.01.  Significantly higher than at pre-
exercise (within trial), †, p < .01. 
Figure 2.  Concentration of circulating T cells expressing GHS-R1a in response to 1 h cycling 
at 75% V
.
O2peak (EX) or rest (REST).  Values are means ± SD, n = 9.  Significantly higher 
than REST at that time, *, p < .05.  Significantly higher than at pre-exercise (within trial), †, 
p < .05. 
Figure 3. Concentration of circulating CD14+ monocytes expressing GHS-R1a in response to 
1 h cycling at 75% V
.
O2peak (EX) or rest (REST).  Values are means ± SD, n = 9.  
Significantly higher than REST at that time, *, p < .05; **, p < .01.   
Figure 4.  Plasma acylated ghrelin concentration in response to 1 h cycling at 75% V
.
O2peak 
(EX) or rest (REST).  Values are means ± SD, n = 8. Significantly lower than REST at that 
time, *, p < .05; **, p < .01.  Significantly lower than at pre-exercise (within trial), ††, p < .01. 
Significantly higher than at 10:00 (within trial), †, p < .05. 
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Table 1. Lymphocyte, CD3+ T cell and CD14+ monocyte numbers, proportion of cells 
expressing the growth hormone secretagogue receptor (GHS-R1a) and the density of GHS-
R1a expression on each cell type in active participants after acute exercise (EX) and rest 
(REST) and in sedentary controls at rest.   
 Pre-exercise 
(10:00) 
0 h post-exercise 
(11:00) 
1 h post-exercise 
(12:00) 
2 h post-exercise 
(13:00) 
Lymphocyte count (x 109 cells.l-1) 
EX 
REST 
SEDENTARY 
1.98 (0.33) 
1.90 (0.32) 
2.16 (0.51) 
2.64 (0.71)a,d 
1.91 (0.30) 
1.67 (0.44) 
1.79 (0.48) 
1.62 (0.29)b,d 
1.86 (0.30) 
Proportion of lymphocytes expressing GHS-R1a (%) 
EX 
REST 
SEDENTARY 
10.4 (2.9) 
15.4 (11.8) 
4.0 (2.5)e 
19.0 (4.6) 
12.0 (12.8) 
26.0 (12.0)a,c 
8.3 (4.1) 
17.3 (10.2)b,c 
9.4 (7.5) 
Density of GHS-R1a expression on total lymphocytes (GMFI)  
EX 
REST 
SEDENTARY 
48.3 (20.2) 
57.5 (19.1) 
43.6 (5.5) 
52.2 (21.2) 
60.1 (19.0) 
49.6 (12.1) 
53.8 (15.3) 
45.7 (17.8) 
57.4 (25.7) 
CD3+ count (x 109 cells.l-1) 
EX 
REST 
SEDENTARY 
1.20 (0.20) 
1.19 (0.24) 
1.30 (0.35) 
1.58 (0.45)b,d  
1.19( 0.19) 
1.05 (0.30) 
1.11 (0.28) 
0.98 (0.17)b,d 
1.18 (0.21) 
Proportion of CD3+ cells expressing GHS-R1a (%)  
EX 6.22 (3.80) 15.06 (8.75)a,c 9.09 (5.40) 7.77 (4.92) 
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REST 
SEDENTARY 
4.90 (3.03) 
3.14 (3.4) 
5.38 (3.89) 4.33 (2.50) 4.09 (2.71) 
Density of GHS-R1a expression on CD3+ cells (GMFI)  
EX 
REST 
SEDENTARY 
50.0 (20.3) 
62.5 (24.7) 
46.9 (6.8) 
54.5 (21.1) 
63.8 (21.0) 
56.9 (12.2) 
56.4 (15.6) 
43.1 (16.5) 
60.6 (26.1) 
Monocyte count (x 109 cells.l-1) 
EX 
REST 
SEDENTARY 
0.50 (0.16) 
0.43 (0.12) 
0.46 (0.15) 
0.47 (0.16) 
0.36 (0.07) 
0.72 (0.16)a,d 
0.48 (0.19) 
0.71 (0.21)a,c 
0.44 (0.09) 
Proportion of CD14+ monocytes expressing GHS-R1a (%) 
EX 
REST 
SEDENTARY 
12.9 (7.7) 
12.1 (6.6) 
16.8 (6.2) 
22.6 (13.8)b 
10.9 (8.7) 
16.3 (9.4)a 
8.1 (3.88) 
10.3 (5.8) 
8.0 (3.6) 
Density of GHS-R1a expression on CD14+ monocytes (GMFI)  
EX 
REST 
SEDENTARY 
45.9 (15.5) 
53.5 (17.9) 
48.7 (20.2) 
44.5 (15.6) 
52.2 (15.5) 
39.3 (9.0) 
46.9 (12.4) 
38.0 (13.0) 
47.1 (18.1) 
Values are means (SD).   GMFI; geometric mean fluorescence intensity 
a, significantly different from REST at that time, p < .01 
b significantly different from REST at that time, p < .05 
c significantly different from pre-exercise values, p < .01 
d significantly different from pre-exercise values, p < .05 
e significantly different from REST at that time, p < .05 
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Figure 2 
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Figure 3  
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Figure 4 
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